Source:http://linkedlifedata.com/resource/pubmed/id/16838024
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2006-8-23
|
| pubmed:abstractText |
Acute lymphoblastic leukemia (ALL) in the elderly is characterized by its ominous prognosis. On the other hand, imatinib has demonstrated remarkable, although transient, activity in relapsed and refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL), which prompted us to assess the use of imatinib in previously untreated elderly patients. ALL patients aged 55 years or older were given steroids during 1 week. Ph+ve cases were then offered a chemotherapy-based induction followed by a consolidation phase with imatinib and steroids during 2 months. Patients in complete response (CR) after consolidation were given 10 maintenance blocks of alternating chemotherapy, including two additional 2-month blocks of imatinib. Thirty patients were included in this study and are compared with 21 historical controls. Out of 29 assessable patients, 21 (72%, confidence interval (CI): 53-87%) were in CR after induction chemotherapy vs 6/21 (29%, CI: 11-52%) in controls (P=0.003). Five additional CRs were obtained after salvage with imatinib and four after salvage with additional chemotherapy in the control group. Overall survival (OS) is 66% at 1 year vs 43% in the control group (P=0.005). The 1-year relapse-free survival is 58 vs 11% (P=0.0003). The use of imatinib in elderly patients with Ph+ ALL is very likely to improve outcome, including OS.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0887-6924
|
| pubmed:author |
pubmed-author:BénéM-CMC,
pubmed-author:BerthaudPP,
pubmed-author:Bilhou-NaberaCC,
pubmed-author:BolognaSS,
pubmed-author:BuzynAA,
pubmed-author:CaillèresSS,
pubmed-author:CastaigneSS,
pubmed-author:CosoDD,
pubmed-author:DarreSS,
pubmed-author:DelabesseEE,
pubmed-author:DelainMM,
pubmed-author:DelannoyAA,
pubmed-author:DombretHH,
pubmed-author:DubruilleVV,
pubmed-author:FohrerCC,
pubmed-author:GarbanFF,
pubmed-author:IsnardFF,
pubmed-author:LegrandOO,
pubmed-author:LhéritierVV,
pubmed-author:RaceGG,
pubmed-author:RaffouxEE,
pubmed-author:RemanOO,
pubmed-author:Rigal-HuguetFF,
pubmed-author:SonetAA,
pubmed-author:ThomasXX,
pubmed-author:TurlurePP
|
| pubmed:issnType |
Print
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1526-32
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16838024-Aged,
pubmed-meshheading:16838024-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16838024-Disease-Free Survival,
pubmed-meshheading:16838024-Humans,
pubmed-meshheading:16838024-Methylprednisolone,
pubmed-meshheading:16838024-Philadelphia Chromosome,
pubmed-meshheading:16838024-Piperazines,
pubmed-meshheading:16838024-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:16838024-Pyrimidines,
pubmed-meshheading:16838024-Stem Cell Transplantation,
pubmed-meshheading:16838024-Treatment Outcome
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study.
|
| pubmed:affiliation |
Department of Hematology, Hôpital de Jolimont, Haine-Saint-Paul, Belgium. a.delannoy@skynet.be
|
| pubmed:publicationType |
Journal Article
|